SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is gaining traction, with community members highlighting its availability on Phantom Wallet and relative stability amidst market fluctuations. The crypto is being touted as a potential "moon" candidate, with buyers sharing enthusiasm. Conversations are centered on its performance within the Solana ecosystem.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

Moo Deng

MOODENG is trending as traders discuss recent price volatility and potential for a breakout. Community members are debating entry points, with some pointing to technical analysis patterns, while others express skepticism, citing its meme coin status and past performance. The coin's listing on Robinhood and upcoming birthday are also being mentioned as potential catalysts.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid discussions about a potential recall of specific lots and the impact on revenue, with community members analyzing the company's response and comparing it to similar situations with competitors. Some traders are interpreting recent stock sales by the CEO, alongside an FDA safety notice, while others suggest potential manufacturing issues. Despite concerns, many community members express confidence in the company's long-term growth and potential for a buyback.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as community members discuss its potential as a Bitcoin-native meme coin, emphasizing its fair launch and strong community. Some see it as a compelling opportunity within the crypto space, drawing comparisons to other popular meme coins and highlighting its unique position on the Bitcoin network. Community members are actively sharing insights and expressing bullish sentiment, with some anticipating significant growth and exchange listings.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to growing community engagement and real-world applications, with discussions focusing on its expanding ecosystem and the potential for significant growth. Community members highlight KENDU's unique approach as a permissionless brand, its active IRL presence, and the increasing number of holders. The recent release of a new website is also generating excitement, with many expressing confidence in KENDU's long-term potential.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the stock price continues to drop post FDA approval, leading to discussions around management, dilution, and future prospects. The community is debating whether the current price represents a buying opportunity or reflects deeper issues with the company's leadership and commercialization strategy. Some traders are noting potential short squeeze setups due to high short interest.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as discussions surge around its advancements in quantum computing, particularly error correction using AMD chips, and a partnership with HSBC. Community members are debating the impact of these developments on IBM's growth and potential for future gains, while some express skepticism, citing mixed reactions to recent earnings and slower growth in certain sectors. Despite differing opinions, IBM's central role in the ongoing quantum computing race and AI remains a key talking point.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors discuss dividend payouts, NAV erosion, and overall profitability; some express concern over the fund's long-term viability. Community members are weighing strategies like reinvesting dividends versus taking profits, with some considering alternative high-yield ETFs.  Broader discussions include the impact of market volatility and potential reverse splits.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending as the community rallies around its lifestyle brand and growing mindshare. Discussions highlight upcoming events featuring sponsored athletes like Karolina Arm, a pro MMA fighter. The community emphasizes that it's more than just a meme; it's a lifestyle with real-world partnerships and a dedicated team.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

<ul class="summary-bullets"><li>Under the deal, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right.&nbsp;</li><li>The transaction is expected to close in the fourth quarter of 2025, subject to satisfaction of the closing conditions. &nbsp;</li></ul>Eli Lilly and Company (LLY) said on Friday that it has entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (ADVM) for a total potential per share consideration of up to $12.47.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html">deal</a>, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right. The upfront cash payment, however, represents a discount of about 15% from the stock’s closing price on Thursday.The transaction is expected to close in the fourth quarter of 2025, subject to satisfaction of the closing conditions.<h2 class="st-heading-2">Board’s View</h2>Adverum said the transaction was unanimously approved by its board of directors following an evaluation of strategic alternatives and discussions with potential partners and buyers. It added that the board believes the agreement with Lilly is in Adverum's and its stockholders' best interests.The acquisition includes Adverum’s lead product candidate Ixo-vec, a late-stage gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose. The milestone payments in the deal are associated with the development of the gene therapy, including U.S. approval.<h2 class="st-heading-2">Fund Arrangements</h2>Adverum has also entered into a Promissory Note with Lilly in conjunction with the transaction that enables it to receive a loan of up to $65 million from Lilly, drawable in four installments, subject to specified conditions. The loan can be used to support ongoing Ixo-vec clinical trials and registrational development activities prior to the anticipated closing of the transaction, it said.Shares of ADVM soared 3% on Friday morning at the time of writing. On Stocktwits, retail sentiment around ADVM soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ADVM">ADVM stock</a> is down by 7% this year and by about 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gm-reportedly-lays-off-over-200-employees-days-after-raising-2025-earnings-guidance/cLGJFcKR3tb">GM Reportedly Lays Off Over 200 Employees Days After Raising 2025 Earnings Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly To Acquire Adverum Biotechnologies

Under the deal, Lilly will commence a tender offer to acquire all of the outstanding shares of Adverum common stock at a per-share price of $3.56, payable in cash at closing, plus milestone payments of up to $8.91 per contingent value right. 

Equity

Lilly to Acquire Adverum Biotechnologies

Lilly to Acquire Adverum Biotechnologies Lilly to Acquire Adverum Biotechnologies PR Newswire INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 Adverum's lead program, Ixo-vec, is a Phase 3 gene...

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial Lilly's baricitinib delivered near-complete...

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis Lilly's EBGLYSS...

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LLY News

LLYLilly(Eli) & Co